Published in Cell on May 25, 2012
FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol (2013) 2.83
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Roles of F-box proteins in cancer. Nat Rev Cancer (2014) 1.51
Pathogen signatures activate a ubiquitination pathway that modulates the function of the metabolic checkpoint kinase mTOR. Nat Immunol (2013) 1.46
Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Nat Rev Cancer (2012) 1.33
Posttranslational regulation of Akt in human cancer. Cell Biosci (2014) 1.27
Skp2-Mediated RagA Ubiquitination Elicits a Negative Feedback to Prevent Amino-Acid-Dependent mTORC1 Hyperactivation by Recruiting GATOR1. Mol Cell (2015) 1.19
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol Cell (2014) 1.19
Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response. J Biol Chem (2012) 1.07
Regulation of Akt signaling by sirtuins: its implication in cardiac hypertrophy and aging. Circ Res (2014) 1.06
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Front Oncol (2012) 1.04
Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene (2013) 1.03
Rapid and widespread suppression of self-renewal by microRNA-203 during epidermal differentiation. Development (2013) 0.99
Skp2-macroH2A1-CDK8 axis orchestrates G2/M transition and tumorigenesis. Nat Commun (2015) 0.98
Mediator kinase module and human tumorigenesis. Crit Rev Biochem Mol Biol (2015) 0.98
Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Mol Cell (2015) 0.97
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest (2014) 0.97
Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. Br J Cancer (2014) 0.96
Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity. Nat Commun (2014) 0.94
MiR-7 triggers cell cycle arrest at the G1/S transition by targeting multiple genes including Skp2 and Psme3. PLoS One (2013) 0.94
Structural insights into the TRIM family of ubiquitin E3 ligases. Cell Res (2014) 0.93
Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent. PLoS One (2012) 0.92
SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget (2015) 0.92
Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cells. Oncotarget (2015) 0.91
Skp2: a dream target in the coming age of cancer therapy. Cell Cycle (2014) 0.90
Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling. Sci Rep (2013) 0.90
Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PLoS One (2012) 0.90
TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res (2013) 0.90
Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res (2014) 0.88
The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway. Cancer Cell Int (2014) 0.88
MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal (2014) 0.88
Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer. Prostate (2013) 0.87
AKT/PKB Signaling: Navigating the Network. Cell (2017) 0.87
Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells. PLoS One (2015) 0.86
E3-ligase Skp2 predicts poor prognosis and maintains cancer stem cell pool in nasopharyngeal carcinoma. Oncotarget (2014) 0.86
Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci Signal (2013) 0.85
The Rho family member RhoE interacts with Skp2 and is degraded at the proteasome during cell cycle progression. J Biol Chem (2013) 0.83
Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle. Cell Cycle (2013) 0.82
The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. Mol Cell (2016) 0.82
Targeting ubiquitination for cancer therapies. Future Med Chem (2015) 0.82
A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway. J Hematol Oncol (2016) 0.81
Antitumor mechanisms when pRb and p53 are genetically inactivated. Oncogene (2014) 0.81
Competing to coordinate cell fate decisions: the MST2-Raf-1 signaling device. Cell Cycle (2015) 0.81
Histone methylation modifiers in cellular signaling pathways. Cell Mol Life Sci (2015) 0.81
SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget (2015) 0.81
Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less. Receptors Clin Investig (2014) 0.80
The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα. PLoS One (2013) 0.80
Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1. Oncotarget (2016) 0.79
Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications. Int J Mol Sci (2015) 0.79
Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res (2016) 0.79
β-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling. Nat Commun (2015) 0.79
Akt: a new activation mechanism. Cell Res (2014) 0.78
HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res (2015) 0.78
Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol (2015) 0.78
The sweet trap in tumors: aerobic glycolysis and potential targets for therapy. Oncotarget (2016) 0.78
The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways. J Biol Chem (2017) 0.77
NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem-Like Cells in Adenoid Cystic Carcinoma. Clin Cancer Res (2016) 0.77
Small molecule therapeutics targeting F-box proteins in cancer. Semin Cancer Biol (2015) 0.77
Skp2 is required for Aurora B activation in cell mitosis and spindle checkpoint. Cell Cycle (2015) 0.77
Rh2E2, a novel metabolic suppressor, specifically inhibits energy-based metabolism of tumor cells. Oncotarget (2016) 0.77
Cellular context-mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis. Mol Biol Cell (2015) 0.77
IL-17A promotes the proliferation of human nasopharyngeal carcinoma cells through p300-mediated Akt1 acetylation. Oncol Lett (2017) 0.76
Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist. Oncogene (2017) 0.76
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun (2016) 0.76
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer. Oncogene (2015) 0.76
Skp1 in lung cancer: clinical significance and therapeutic efficacy of its small molecule inhibitors. Oncotarget (2015) 0.76
Systemic insulin sensitivity is regulated by GPS2 inhibition of AKT ubiquitination and activation in adipose tissue. Mol Metab (2016) 0.76
Phosphorylation of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) by Akt promotes stability and mitogenic function of S-phase kinase-associated protein-2 (Skp2). J Biol Chem (2014) 0.76
Overexpression of PTP4A3 is associated with metastasis and unfavorable prognosis in bladder cancer. World J Urol (2015) 0.76
Regulation of cancer stem cells by RING finger ubiquitin ligases. Stem Cell Investig (2014) 0.76
The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells. J Cancer Res Clin Oncol (2012) 0.76
Curcumin inhibits cell growth and invasion and induces apoptosis through down-regulation of Skp2 in pancreatic cancer cells. Am J Cancer Res (2016) 0.76
Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents. J Cell Biochem (2014) 0.75
Assessing the clinical utility of genomic expression data across human cancers. Oncotarget (2016) 0.75
Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice. EMBO J (2016) 0.75
Phosphorylation by mTORC1 stablizes Skp2 and regulates its oncogenic function in gastric cancer. Mol Cancer (2017) 0.75
The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma. Mol Brain (2015) 0.75
A novel read-through transcript JMJD7-PLA2G4B regulates head and neck squamous cell carcinoma cell proliferation and survival. Oncotarget (2016) 0.75
Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia (2016) 0.75
Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. J Transl Med (2016) 0.75
The Akt-mTOR axis is a pivotal regulator of eccentric hypertrophy during volume overload. Sci Rep (2015) 0.75
Virtual drug design: Skp1-Skp2 inhibition targets cancer stem cells. Asian J Androl (2013) 0.75
Cullin-RING ligases in regulation of autophagy. Cell Div (2016) 0.75
USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. EMBO J (2017) 0.75
RNAi-mediated silencing of the Skp-2 gene causes inhibition of growth and induction of apoptosis in human renal carcinoma cells. Int J Clin Exp Pathol (2014) 0.75
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin. Molecules (2017) 0.75
Increased mitochondrial fusion allows the survival of older animals in diverse C. elegans longevity pathways. Nat Commun (2017) 0.75
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
On the origin of cancer cells. Science (1956) 49.55
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer (2006) 6.76
Glycolysis inhibition for anticancer treatment. Oncogene (2006) 6.55
Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell (2010) 5.83
Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J (2000) 5.61
c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A (1997) 5.43
Direct activation of protein kinases by unanchored polyubiquitin chains. Nature (2009) 4.65
The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science (2009) 4.63
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
Akt-dependent transformation: there is more to growth than just surviving. Oncogene (2005) 3.91
The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell (2003) 3.87
Skp2 regulates Myc protein stability and activity. Mol Cell (2003) 3.85
Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem (2000) 3.74
Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem (2003) 3.68
Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell (2007) 3.54
PKB binding proteins. Getting in on the Akt. Cell (2002) 3.34
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol (2008) 2.98
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 2.89
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ (2001) 2.85
Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol (2009) 2.76
Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem (1999) 2.13
AH/PH domain-mediated interaction between Akt molecules and its potential role in Akt regulation. Mol Cell Biol (1995) 2.03
Oxygen sensors at the crossroad of metabolism. Cell Metab (2009) 1.98
Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol (2010) 1.93
Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice. Nat Genet (2009) 1.62
Regulation of Akt signaling activation by ubiquitination. Cell Cycle (2010) 1.28
Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol (2011) 1.21
Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene (2010) 1.21
Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol (2002) 1.20
Regulation of Skp2 expression and activity and its role in cancer progression. ScientificWorldJournal (2010) 1.19
Angiogenic acceleration of Neu induced mammary tumor progression and metastasis. Cancer Res (2004) 1.12
Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB J (2007) 1.06
Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas. Clin Cancer Res (2006) 0.97
Novel ARF/p53-independent senescence pathways in cancer repression. J Mol Med (Berl) (2011) 0.95
On the InterAktion between hexokinase and the mitochondrion. Dev Cell (2004) 0.93
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Multiplex amplification of large sets of human exons. Nat Methods (2007) 15.11
MOM: maximum oligonucleotide mapping. Bioinformatics (2009) 13.75
Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol (2009) 11.18
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 9.80
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol (2009) 7.59
Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science (2009) 6.96
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell (2004) 6.13
Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell (2007) 5.94
Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A (2008) 5.94
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J (2004) 4.95
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science (2009) 4.63
Generation of induced pluripotent stem cell lines from adult rat cells. Cell Stem Cell (2008) 4.52
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Digital RNA allelotyping reveals tissue-specific and allele-specific gene expression in human. Nat Methods (2009) 4.38
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
Pausing of RNA polymerase II disrupts DNA-specified nucleosome organization to enable precise gene regulation. Cell (2010) 4.28
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
Global analysis of short RNAs reveals widespread promoter-proximal stalling and arrest of Pol II in Drosophila. Science (2009) 4.13
Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89
The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell (2003) 3.87
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol (2011) 3.85
VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev (2004) 3.82
Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (2005) 3.80
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell (2005) 3.67
Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol (2006) 3.63
Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J (2006) 3.53
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell (2005) 3.51
Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell (2007) 3.42
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell (2013) 3.32
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell (2008) 3.32
Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell (2004) 3.27
Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat Neurosci (2011) 3.27
Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol (2007) 3.23
The mechanisms of PML-nuclear body formation. Mol Cell (2006) 3.22
PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 3.21
Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol (2004) 3.14
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A (2002) 3.08
TRIM24 links a non-canonical histone signature to breast cancer. Nature (2010) 2.99
Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol (2009) 2.91
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res (2007) 2.89
The transcription unit architecture of the Escherichia coli genome. Nat Biotechnol (2009) 2.85
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics (2005) 2.81
A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells. PLoS Genet (2009) 2.78
Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol (2009) 2.76
Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature (2002) 2.68
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature (2013) 2.67
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64
Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol (2003) 2.64
A new mutational AKTivation in the PI3K pathway. Cancer Cell (2007) 2.62
Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol (2005) 2.62
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol (2006) 2.60
Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem (2003) 2.59
Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res (2005) 2.58
p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell (2011) 2.58
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) (2010) 2.57
KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55
p57 is required for quiescence and maintenance of adult hematopoietic stem cells. Cell Stem Cell (2011) 2.54
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell (2004) 2.53
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol (2010) 2.52
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell Biol (2004) 2.50
P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res (2004) 2.48
Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A (2003) 2.45
Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol (2006) 2.45
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell (2007) 2.41
Multiplex padlock targeted sequencing reveals human hypermutable CpG variations. Genome Res (2009) 2.38
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood (2008) 2.36
CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol (2010) 2.36
beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell (2002) 2.33
Next-generation digital information storage in DNA. Science (2012) 2.33